Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CCL4 Products |
| Gene Delivery | CCR5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to perform functional assays. |
View CCR5 Products |
| Benchmark Ab | Anti-CCL4 (Sequence of clinical-grade reference clones) Recombinant positive control. |
View CCL4 Products |
| Validator | CCL4 siRNA Set For knockdown verification. |
View CCL4 Products |
| Related Target A | CCR5 Primary G-protein coupled receptor for CCL4, crucial for functional chemotaxis validation. |
View CCR5 Products |
| Related Target B | CCL3 Highly homologous chemokine (MIP-1 alpha) sharing CCR5 receptor; essential for counter-screening. |
View CCL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against highly homologous CCL3 (MIP-1a) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis |
| Chemokine aggregation interfering with affinity (KD) measurements | Monomeric-grade recombinant proteins with controlled aggregation profiles |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CCL4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CCL4/MIP-1 beta axis is gaining substantial traction across immunology and oncology. CCL4 acts as a critical chemoattractant for CCR5-expressing immune cells, including regulatory T cells (Tregs), macrophages, and dendritic cells. In the tumor microenvironment (TME), CCL4 can promote immunosuppression by recruiting pro-tumorigenic myeloid cells, making it a high-value target for monoclonal antibodies and combination therapies.
"The race for CCL4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination regimens and bispecific modalities. As first-generation CCR5/CCL4 pathway inhibitors reach clinical evaluation, the next wave of R&D is targeting highly selective blockade to avoid systemic immune disruption while achieving localized efficacy."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutions, Biotech Consortiums | Solid Tumors, Inflammatory Diseases | High-purity soluble CCL4 antigen for precise epitope mapping and affinity determination |
| Bispecific / Multi-specific | Oncology-focused Biopharma | Immuno-oncology (Cold Tumors) | Selectivity panels (CCL4 vs CCL3) to ensure target-specific binding without off-target sink |
| Small Molecule (CCR5 Antagonists) | Global Pharmaceutical Corporates | HIV, NASH, Metastatic Cancer | Lentivirus for stable CCR5 expression to support high-throughput calcium flux and chemotaxis screening |